Patents covering CM-101, potential PSC therapy, given in Brazil, Israel
Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…
Cholangitis
Bexotegrast shows positive signs as PSC treatment in Phase 2 trial
Pliant Therapeutics’ investigational oral treatment bexotegrast safely eases itching and is associated with signs of better liver function and less liver scarring, or fibrosis, in…
FDA to review approval application for seladelpar as PBC treatment
The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral investigational treatment for adults with…
Seladelpar lowers levels of molecule driving itch with PBC: Phase 3 trial
Seladelpar, an experimental oral therapy by CymaBay Therapeutics, significantly lowered blood levels of an itch-associated molecule called interleukin-31 (IL-31) in people with…
Health Canada Approves Ocaliva for Autoimmune Liver Disease Patients
Canadian patients with the autoimmune liver disease primary biliary cholangitis (PBC) saw the first approval of a new drug for their condition in more than…
Genkyotex’s GKT831 Drug Moves to Phase 2 Trial After Winning FDA Investigational New Drug Status
The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase…
First Patient Enrolled in Phase 2 Clinical Trial of Elafibranor for Bile Duct Disease
GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile duct disease known as primary…
New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments
A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver…
Enanta’s EDP-305 Therapy Shows Promise in Treating Non-Alcoholic Fatty Liver Disease
Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…
Recent Posts
- Patient identification guidelines may help diagnose biliary atresia earlier
- Hepatitis B gene-editing therapy PBGENE-HBV shows early promise
- 2nd liver transplant linked to good outcomes in PSC
- AI models may aid intrahepatic cholestasis of pregnancy prediction
- With so many specialists, scheduling appointments can be tricky